One mechanism for disrupting the MLL gene in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is through partial tandem duplication (MLL-PTD); however, the mechanism by which MLL-PTD contributes to MDS and AML development and maintenance is currently unknown. Herein, we investi- 
Introduction
Hematopoiesis requires coordinate changes in gene expression to control the process of cell fates for self-renewal, differentiation, apoptosis, and maturation. Dysregulation of transcriptional controls in hematopoiesis contributes to myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Recurrent chromosomal translocations and gene mutations are found in MDS and AML that affect transcriptional regulators, including transcription factors and epigenetic regulators, such as RUNX1, CBF␤, MLL, and EZH2. [1] [2] [3] [4] A significant fraction of MDS and MDS/AML have RUNX1 mutations or MLL partial tandem duplication (MLL-PTD), [5] [6] [7] [8] whereas nearly half of all AML cases are associated with aberrations of MLL or CBF genes. [9] [10] [11] The Mixed-Lineage Leukemia (MLL) gene was isolated as a common target of chromosomal translocations occurring at 11q23. 9, 10 These translocations fuse MLL with more than 70 different partner genes. The SET domain of MLL has histone methyltransferase activity that specifically methylates lysine 4 on histone H3 (H3K4), a modification typically associated with transcriptionally active regions of chromatin. 12, 13 The MLL-PTD was first observed in de novo AML with a normal karyotype or trisomy 11. [14] [15] [16] Cloning of this region revealed partial duplications within the 5Ј region of the MLL gene. These duplications consist of an in-frame repetition of MLL exons in a 5Ј to 3Ј direction and produce an elongated protein. 15 The incidence of MLL-PTD was 5.4% in one study of 956 unselected cases of AML, whereas another series detected MLL-PTD in 6.4% of 988 unselected adult and childhood AML. 17, 18 All studies confirmed that MLL-PTD is predominantly found in cytogenetically normal AML or in AML with trisomy 11 as a sole cytogenetic abnormality. In several but not all studies, patients with MLL-PTD had shorter disease-free survival and overall survival rates, although only the shortened disease-free survival rate was statistically significant. [17] [18] [19] How MLL-PTD contributes to MDS or AML is unclear. Two observations reveal potential mechanisms whereby MLL-PTD may disturb normal hematopoiesis: (1) repetitive DNA-binding domains (AT hooks and CXXC domain), present in MLL-PTD, exhibit transactivation potential in vitro 20 ; and (2) the release of wild-type (WT) MLL gene suppression in MLL-PTD-positive AML by inhibitors of DNA methyltransferase and histone deacetylase that induce AML blast apoptosis. 21 These 2 findings suggest that the MLL-PTD pathway(s) of leukemic transformation are different from those resulting from the fusion of MLL-fused with partners other than itself. Consistent with this notion is the observation that gene expression profiling separates the MLL-PTD AML from those AML containing chimeric MLL gene fusions. 22 Thus, in vitro and in vivo modeling is needed to address the specific genetic and epigenetic changes associated with MLL-PTD AML.
We generated a Mll-PTD knock-in mouse model in which its expression is regulated by endogenous promoter, to study the function of Mll-PTD in vitro and in vivo and to identify its downstream targets. Although the Mll PTD/WT mice do not develop leukemia, they provide a powerful genetic tool to identify disruptions in normal cellular regulation as a result of this mutation, as well as a model to characterize the contribution of the Mll-PTD in leukemogenesis. 23, 24 Our initial studies characterizing the Mll PTD/WT mice showed that pathways involving myeloid progenitor self-renewal and proliferation are disrupted as a direct result of the Mll-PTD. 24 However, a functional dissection of its effect on phenotypically well-defined hematopoietic stem and progenitor cell (HSPC) populations from the Mll PTD/WT mice has thus far not been performed. In this report, we further analyzed hematopoiesis in the Mll-PTD knock-in mouse with a specific focus on the function of HSPCs.
Methods

Mice
The Mll PTD/WT knock-in mice (CD45.2) were previously described. 24 B6.SJL (CD45.1) mice were obtained from the CCHMC/CBDI mouse core. C57Bl/6 ϫ B6.SJL-F1 (CD45.1/CD45.2) were bred in house. All animals were housed in the animal barrier facility at Cincinnati Children's Hospital Medical Center. All animal studies were conducted according to an approved Institutional Animal Care and Use Committee protocol and federal regulations.
Single-cell culture and differentiation assessment
The method of single-cell culture was described previously. 25 Briefly, a round-bottom 96-well plate (BD Biosciences) was used for cell culture. Each well contained 200 L IMDM (Mediatech) supplemented with cytokines (20 ng/mL murine stem cell factor (mSCF) and 20 ng/mL murine thrombopoietin (mTPO), both from PeproTech; 20 ng/mL human G-CSF, 10 ng/mL mIL-3, Peprotech; and 4 U/mL human erythropoietin). Automated deposition of Lin Ϫ c-Kit ϩ Sca1 ϩ CD150 ϩ CD48 Ϫ cells (LSK/SLAM ϩ ) or Lin Ϫ c-Kit ϩ Sca1 ϩ CD150 ϩor Ϫ CD48 ϩ cells (LSK/SLAM Ϫ ) or granulocytemacrophage progenitor (Lin Ϫ c-kit ϩ Sca1 Ϫ CD34 ϩ CD16/32 hi ; GMP) single cell was carried out by a FACSAria sorter. After cell sorting, the presence of one cell per well was verified under an inverted microscope (Olympus CKX31). The cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 in air. Final evaluation of cell division and colony formation was conducted at day 14 of culture. Cytospin slides prepared from the colonies were stained with Camco Stain Pak (Cambridge Diagnostic Inc) according to the manufacturer's suggested procedures. Slides were analyzed on a Motic BA310 microscope system (Motic Inc).
5-FU treatment and HSC analysis
A single dose (150 mg/kg) of 5-fluorouracil (5-FU; Sigma-Aldrich) was administered intraperitoneally into Mll PTD/WT or WT mice (4-8 per group). Peripheral blood (PB) counts were measured every 3-4 days. BM cells were collected at different time points and were stained for LSK, CD150, and CD48 antibodies followed by FACS analysis.
Statistical analysis
The Student t test was used to determine the statistical differences between experimental and control groups.
Full methods for flow cytometry, spleen colony-formation assay, BM transplantation assay, CFU assay, and Western blotting are available in supplemental Methods (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
Results
BM content of HSPCs is reduced in number in Mll PTD/WT mice
We analyzed the hematopoiesis of Mll PTD/WT mice with a specific focus on the function of HSPCs, including LSK, LSK/SLAM, long-term HSCs (LT-HSCs), short-term HSCs (ST-HSCs), multipotent progenitors (Lin Ϫ c-Kit ϩ Sca1 ϩ CD34 ϩ CD135 ϩ ; MPPs), and hematopoietic progenitor cells (Lin Ϫ c-Kit ϩ Sca1 Ϫ ; HPCs). Consistent with our original report, 23 no significant changes in specific blood lineages were observed in Mll PTD/WT mice, in either total BM cellularity or PB counts (data not shown). However, the Mll PTD/WT mice had significantly reduced numbers of immunophentoypically defined LSKs at 8 and 12 months of age and LSK/ SLAM ϩ populations in the BM at 4, 8, and 12 months of age compared with their age-and sex-matched WT littermate controls ( Figure 1A-C) . In Mll PTD/WT mice, we found similar trends for reduction in LSKs and LSK/SLAM ϩ populations in the spleen and PB at 4, 8, and 12 months of age compared with their age-and sex-matched WT littermate controls (data not shown). Mll PTD/WT mice exhibit an increase in the GMP population at the expense of the megakaryocyte-erythroid progenitor cells (Lin Ϫ c-Kit ϩ Sca1 Ϫ CD34 Ϫ CD16/32 low ; MEP) population ( Figure 1D ). To determine the cellular mechanism responsible for these effects, we analyzed BM cells for apoptotic and cell cycle changes at steady-state hematopoiesis. There was a significant increase in apoptosis of the LSK population of Mll PTD/WT mice and a trend toward increased apoptosis in the LK population ( Figure 1E ). The Mll PTD/WT LSK population showed a significant increase in S ϩ G 2 /M phase but reduction in G 0 /G 1 phase compared with WT controls ( Figure 1F ). There was a modest (not significant) reduction of S ϩ G 2 /M phase for the Mll PTD/WT LK population. Our data suggest that the increased rate of apoptosis may partially explain the loss of the LSK and LSK/SLAM ϩ populations in Mll PTD/WT mice. MLL is involved in epigenetic regulation of H3K4 methylation. It is still unclear how MLL-PTD affects MLL methyltransferase activity, which is still present in the PTD allele. We purified HSPCs from Mll PTD/WT and WT controls and found that there is no global change in H3K4me3 and H3K4me2 methylation levels ( Figure 1G) . Thus, the function of Mll PTD/WT could be locus-specific.
Expansion of Mll PTD/WT mice HSPCs in CFU-spleen and replating assays
To dissect the function of Mll PTD/WT HSPCs, we performed standard in vivo CFU-spleen assays with BM-derived HSPCs from age-and sex-matched littermates of 4-month-old Mll PTD/WT and WT controls. We found a 50% reduction in the number of day 8 CFU-spleen and day 12 CFU-spleen colonies derived from Mll PTD/WT BM compared with WT BM, indicating reduced numbers of early and committed Mll PTD/WT progenitors (Figure 2A-B) , consistent with the reduction of phenotypically defined early and committed Mll PTD/WT progenitors noted in Figure 1B . CFU-spleen colonies derived from Mll PTD/WT mice BM cells were significantly larger than those seen in controls ( Figure 2C ). M3434 methylcellulose-based medium. We found that Mll PTD/WT BM cells produced significantly more colonies in the second and third replating compared with WT BM cells ( Figure 2D -E). A significant number of dense CFU-MIX colonies were seen in the first and second replating of the Mll PTD/WT BM cells, whereas WT BM cells showed few CFU-MIX clones in the first and rarely in the second replating ( Figure 2F ). These results indicate that Mll PTD/WT BM cells may maintain an immature phenotype longer than the WT BM cells, perhaps because of enhanced self-renewal activity.
Mll PTD/WT BM contains an increased number of competitive repopulating LT-HSCs
To determine whether Mll PTD/WT HSCs exhibit enhanced selfrenewal, we next performed standard BM transplantation (BMT) assays to examine the engraftment potential of 4-month-old Mll PTD/WT HSPCs in vivo ( Figure 3A ). We found increased frequencies of donor-derived reconstitution in the CD45.1/CD45.2 recipient mice at a starting 1:1 ratio of Mll PTD/WT BM cells (CD45.2) with competitor WT cells (CD45.1; Figure 3B ). Up to 90% donor Mll PTD/WT CD45.2 chimerism was observed at 16-to 24-week time points in BM (data not shown) and in PB, whereas WT donor CD45.2 cells maintained ϳ 50% chimerism ( Figure  3B ). We purified the CD45.2 cells from primary recipients at 16 weeks and performed secondary transplantation at a 1:1 ratio with WT competitor cells (CD45.1). The Mll PTD/WT derived cells could still maintain high chimerism (up to 60%-70%) in the recipients, whereas mice receiving WT-derived cells demonstrated low chimerism in BM (data not shown) and PB (1%-2%) at 16 weeks ( Figure 3C ). Calculations showed that Mll PTD/WT BM cells have 6.5 times (primary) and 64.5 times (secondary) more competitive repopulating units (CRU) than do age-and sex-matched WT controls ( Figure 3D ). Our data indicate Mll PTD/WT BM cells have more functional long-term repopulating cells and these cells maintain their activity on transplantation. To examine these findings in more detail, we performed limiting dilution experiments with Mll PTD/WT and WT BM cells. We varied the numbers of WT or Mll PTD/WT BM cells (CD45.2) mixed with 100 000 helper/competitor BM cells (CD45.1), transplanted them into recipient mice, and examined donor-derived cells at various time points ( Figure 3E ). We detected high levels of chimerism (up to 90%) of CD45.2 donor-derived cells from mice transplanted with 1:4 and 1:8 ratios of Mll PTD/WT (CD45.2) cells to helper/competitor BM cells, whereas WT control transplanted mice showed the expected low chimerism at these same ratios (10% and 1%, respectively). There were initially low percentages of reconstitution (5%-10%) by Mll PTD/WT CD45.2 donor-derived cells at the 1:16 and 1:32 ratios, the Mll PTD/WT CD45.2 cells could reach up to 70% and 60% of the PB, respectively, by 6 months ( Figure 3E BLOOD, 2 AUGUST 2012 ⅐ VOLUME 120, NUMBER 5 For personal use only. on April 10, 2017. by guest www.bloodjournal.org From Mll PTD/WT MPPs or GMPs in the recipient mice assessed at 4 months after transplantation, whereas their B-and T-cell reconstitution was comparable with helper cell (CD45.1) reconstitution ( Figure 4D) . A similar myeloid lineage blockade was also found in our limiting dilution BMT assay ( Figure 3E ; and data not shown). The MPP and GMP BMT are highly lymphoid biased (especially B cells rather than T cells in both PB and BM). We used double-sorted GMPs and performed BMT with dose titration. At 6 weeks after transplantation, we found very low reconstitution with GMP cells (Figure 4E) . However, at 12 weeks and 20 weeks, we found significant reconstitution of B cells, T cells, and low percentage of myeloid cells in the PB (Figure 4E-F) .
We also analyzed the BM reconstitution of Mll PTD/WT HSPCderived cells. Although MPP and GMP BMT recipient cells are highly lymphoid biased in PB, they are actually enriched for immunophenotypic GMP populations in the BM of recipient mice. We found similar accumulation of MLL-PTD GMP in the BM of recipients of MLL-PTD LT-HSCs and ST-HSCs (Figure 5A-D) . This lymphoid bias could be the result of a blockade to myeloid, but not lymphoid, differentiation. In support of this concept, we found significant myeloid reconstitution in the BM, but not in the PB ( Figure 5E -F compared with Figure 4D ). We also performed secondary transplantations of MLL-PTD MPP recipient-derived HSPCs and found that they reconstitute secondary recipient mice ( Figure 5G-H Figure 6A-B) . In this assay, WT LT-HSCs will generate all 4 lineages of myeloid cells (erythroid, megakaryocyte, granulocyte, and monocyte); however, committed progenitors will give rise to limited lineages. 26 WT LSK/SLAM ϩ BM cells generated 42% tetra-lineage clones, 42% trilineage clones, and 16% bi-lineage or uni-lineage clones. However, LSK/SLAM ϩ BM cells of Mll PTD/WT mice generated 78% tetralineage clones, 16% tri-lineage clones, and 6% bi-lineage or uni-lineage clones (P Ͻ .001). There was a significant shift toward immaturity of the LSK/SLAM ϩ population in Mll PTD/WT mice. In addition, we found that 15.5% of Mll PTD/WT LSK/SLAM Ϫ BM cells generated tetra-lineage clones, 32% generated tri-lineage clones, and 52% generated bi-lineage or uni-lineage clones. In contrast, WT LSK/SLAM Ϫ BM cells only gave rise to bi-lineage or uni-lineage clones ( Figure 6B ). We also sorted GMP populations from both WT and Mll PTD/WT mice and performed single-cell in vitro cultures under the same conditions. Neither WT-nor Mll PTD/WT -derived GMPs showed clonal growth under these culture conditions, which may be the result of the limited number of single cells (four 96-well plates) we analyzed in this assay ( Figure 6C ). Thus, although 3500 Mll PTD/WT GMP cells could give long-term engraftment in vivo, we could not find any multilineage differentiation under the in vitro single-cell experiment conditions. We conclude that the altered differentiation/ repopulating property activity of Mll PTD/WT HSPCs is reduced as these cells drive toward lineage commitment and differentiation. Alternatively, this in vitro assay may be too stringent and incompatible with cells that have acquired incomplete self-renewal capability. To further address the GMP-altered differentiation/repopulating properties, we sorted BM GMP populations from both WT and Mll PTD/WT mice and performed in vitro CFU replating assays. Compared with WT GMPs, Mll PTD/WT GMP colonies had significantly greater colony formation in the first replating, but not in the second replating. However, the Mll PTD/WT GMP colonies produced colonies on both the third and fourth replating, whereas WT GMP colonies did not ( Figure 6D ).
The differences between WT and Mll PTD/WT colonies are not limited to the clone numbers but also to colony types. The WT GMP cells gave rise to CFU-GM, colony-forming unit-granulocyte (CFU-G), and colony-forming unit macrophage (CFU-M) colonies in the first replating and only gave rise to CFU-G and CFU-M colonies in the second replating. However, the Mll PTD/WT GMP cells produced CFU-MIX, CFU-GM, CFU-G, and CFU-M colonies in the first replating and CFU-GM, CFU-G, and CFU-M colonies in the second replating and third replating, In contrast, the fourth replating only yielded a few CFU-M colonies ( Figure 6E ). We found significant numbers (5%) of dense CFU-MIX colonies in the first replating of the Mll PTD/WT GMPs; however, WT GMP cells yielded 0.1% of CFU-MIX colonies in the first replating. Although we found significant numbers of CFU-GM colonies in the second and third replating of the Mll PTD/WT GMPs, we did not observe CFU-GM colony in the second replating of WT GMP cells ( Figure  6F ). These data suggest that Mll PTD/WT GMPs are less mature and have enhanced replating activity compared with WT GMPs, despite exhibiting similar differentiation potentials in the in vitro assay. These in vitro observations are also consistent with our in vivo BMT assay that revealed that Mll PTD/WT GMP cells have multilineage differentiation potentials and can self-renew.
Rapid expansion and reduced apoptosis of Mll PTD/WT LSK/ SLAM ؉ cells under stress
BM cells from Mll PTD/WT mice after primary and secondary BMTs exhibited elevated rates of apoptosis at steady state (data not shown). It is known that BMT increases stress on HSPCs, which affects the survival, self-renewal, and proliferation of HSPCs. To evaluate stress-induced signaling in HSPCs (independent of BMT), we treated primary mice with a low dose of 5-FU. We first analyzed PB counts and blood lineages but did not find significant differences between Mll PTD/WT and WT groups (data not shown). We further analyzed the HSPCs from the BM of 5-FU-treated mice and found rapid and enhanced expansion of Mll PTD/WT LSK versus WT LSK (3.2-fold vs 1.3-fold, P Ͻ .01) and Mll PTD/WT LSK/SLAM ϩ versus WT LSK/SLAM ϩ (7.1-fold vs 1.2-fold, P Ͻ .01) at 14 days after 5-FU treatment ( Figure 7A-C) . These data indicate that, although Mll PTD/WT mice have fewer LSK and LSK/SLAM ϩ populations at steady state, the surviving fraction of HSPCs exhibits increased proliferation after 5-FU exposure. We also analyzed the apoptosis of HSPCs after low-dose 5-FU treatment and found that WT controls have increased apoptosis, but Mll PTD/WT LSK BM cells (which have increased apoptosis rate without 5-FU treatment) exhibit reduced apoptosis compared with their WT counterpart controls (61.5% compared with 15.4%, P Ͻ .05; Figure 7D ). We also analyzed cell-cycle changes under low-dose 5-FU treatment. The Mll PTD/WT LSK population showed a significant increase in S ϩ G 2 /M phase, but reduction in G 0 /G 1 phase, compared with WT controls (Figure 7E , P Ͻ .01). These results could explain the data from the CFU-spleen and competitive BMT assays. Namely, stress appears to alter the Mll PTD/WT HSPCs in such a way that is permissive for rapid expansion and proliferation/ survival in vivo.
To understand the divergent regulation of survival signaling in Mll PTD/WT BM cells at the molecular level when under normal and stress conditions, we harvested LSK cells from 5-FU-treated mice (both Mll PTD/WT and WT controls) and analyzed the expression of apoptosis-regulating proteins, specifically, Bcl2 family proteins. Among the members of Bcl2 family genes, Bfl1/A1 and Bcl-w were nearly undetectable at both RNA and protein levels (data not shown). We found down-regulation of Mcl-1 and Bcl-2 before and after 5-FU treatment in the Mll PTD/WT LSK BM cells and in their counterparts ( Figure 7F) . Interestingly, reduced expression of both Mcl-1and Bcl-2 in Mll PTD/WT cells might explain increased Mll PTD/WT cell apoptosis at steady state. However, Bcl-XL was significantly up-regulated (up to 10-fold) in Mll PTD/WT 5-FU-treated BM LSK cells, but not in WT LSK cells. We did not find significant changes in Bax or tubulin ( Figure 7F ). This might explain the increased resistance to apoptosis observed in Mll PTD/WT LSKs exposed to 5-FU stress. We also measured the expression of these apoptosis-regulating proteins from the 
Discussion
We examined a mouse model of Mll-PTD to understand the mechanism underlying HSC self-renewal and abnormal phenotypes associated with human MLL-PTD-positive MDS and AML. We found that murine Mll PTD/WT HSPCs exhibit elevated apoptosis at steady state but become proliferative and resistant to apoptosis when expose to stress. Abnormal self-renewal activity provides the Mll PTD/WT HSPCs a greater expansion advantage concurrent with both lymphoid lineage bias and a myeloid terminal differentiation blockade. Although we did not observe frank MDS or AML development in Mll PTD/WT mice, their HSPC phenotypes reflect major features of human MDS. Patients with MDS display hypercellular or hypocellular marrow with dysplastic morphology and impaired maturation (dysmyelopoiesis) in the BM, and PB cytopenias. These hematopoietic defects are thought to manifest when a clonal HSC mutant predominates in the BM, suppressing healthy HSC function. In the early stages of disease, the primary cause of cytopenia is thought to be the result of reduced selfrenewal, increased apoptosis, and blocked differentiation. In about one-third of patients, MDS progresses to secondary AML as additional genetic abnormalities are acquired. Little is known about the molecular mechanisms underlying MDS-associated ineffective hematopoiesis, clonal expansion, and leukemic transformation; therefore, new targeted therapies and experimental models are limited. 28 A limited number of HSPCs of Mll PTD/WT mice could outcompete the WT HSPCs in the same BMT assay. These results indicated that the Mll-PTD provides an advantage for clonal expansion. A second possibility is that these mutant HSC cells suppress the growth and/or survival of the WT HSCs in vivo. Our data also suggest that limiting numbers of Mll-PTD cells undergo clonal expansion over time and eventually outcompete the normal stem cells to become the dominant clone in the BM. This model probably describes the natural progression and development of an abnormal phenotype associated with MDS or AML in the presence of a hematopoietic "stressor." To our knowledge, this is the first report supporting that the MLL-PTD defect functions as a "driver mutation" for MDS or AML stem cell expansion. However, the Mll-PTD by itself does not fully transform the aberrant HSPCs to MDS or AML.
Our previous report has shown that HoxA genes are increased in Mll-PTD mice. HoxA genes have been shown to be important for proliferation and leukemic transformation. However, it is unclear 5, 19 New animal models and mechanistic studies are warranted for modeling human MLL-PTDmediated MDS and AML in mice. We found that the Mll PTD/WT HSPCs, including the GMP population cells, exhibit self-renewal and repopulation activities. Thus, the MDS or leukemogenic clones do not have to be derived from LT-HSCs. This would imply that there is an increased pool of defective HSC (eg, the cancer "cell of origin") that is intrinsically permissive to acquire additional mutations for MDS or AML development. It has recently been shown that human leukemogenesis requires multiple gene mutations. [27] [28] [29] Although Mll PTD/WT mice have fully mature cell types in blood, their HSPCs do not undergo normal differentiation as indicated by a strong myeloid lineage blockade in the ST-HSC, MPP, and GMP populations after BMT and in the limiting dilution BMT ( Figure 4D ; and data not shown). These data demonstrate that the Mll-PTD cannot only alter self-renewal of HSPCs but also induce intrinsic defects toward myeloid lineage differentiation. MLL translocations are involved in AML or ALL (both B-and T-ALL); however, MLL-PTD has been identified only in MDS and AML. 5, 6, 31 The normal B-/T-cell differentiation we found in the Mll PTD/WT HSPCs BMT assay suggests that the Mll-PTD is able to disrupt myeloid (but not lymphoid) lineage differentiation. Notably, the Mll PTD/WT mice HSPC phenotypes observed in our previous reports 23, 24 and in this study are noticeably different from the Mll-Af9 genetic knock-in mouse model that gives rise to AML spontaneously in a short period of time. 32, 33 MLL-AF9, which is described as a gain-of-function mutant, is a potent oncogene for AML development. In contrast, a genetic loss-of-function model for Mll in adult hematopoiesis, Mll ⌬/⌬ , leads to an acute BM failure, which suggests that Mll plays an important role for HSPC fitness and maintenance. 34 Compared with the other 2 genetic models, the molecular mechanism underlying the unique features of Mll PTD/WT mice HSPC remains to be elucidated. Future efforts to identify the downstream target genes of the Mll-PTD protein should provide mechanistic insight into these HSPC phenotypes.
We found that Mll PTD/WT HSPCs are reduced in absolute number during aging, in part because of increased apoptosis. Despite reduced cell survival potential, these cell populations have a proliferative advantage in in vitro colony replating assays, in in vivo CFU-spleen assays, and rapidly expand when transplanted into recipient mice. This appears to be partly because of a Bcl-XL-mediated prosurvival pathway that is preferentially induced in donor Mll PTD/WT HSPCs by the stress conditions intrinsic to transplantation. Bcl-XL has been shown play an important role for the survival and clonal expansion of HSPCs in retroviral transduction followed by BMT or retroviral random integration mediated Bcl-XL gene activation in BMT assays. 35, 36 Although Mll PTD/WT LT-HSCs outcompete WT LT-HSCs in vivo, the Mll PTD/WT -derived ST-HSCs/MPP and GMP populations have selfrenewal capability, rescuing hematopoiesis by giving rise to long-term repopulating cells in recipient mice with an unexpected myeloid differentiation blockade. These findings could help explain the advantage of those HSPCs with MLL-PTD in MDS, secondary sAML, and de novo AML.
Our identification of down-regulated Mcl1 and Bcl2 might be relevant to human MDS because it has been suggested that down-regulation of MCL-1 or BCL2 can be pathogenic in MDS. [37] [38] [39] [40] [41] [42] [43] Antiapoptosis therapy, such as cytokine therapies, has been suggested. [44] [45] [46] However, this should be taken with additional consideration for specific patient groups, as we found up-regulation of Bcl-XL of Mll PTD/WT LSK cells exposed to stress, such as 5-FU treatment or BMT. Some cytokines (eg, erythropoietin and thrombopoietin) up-regulate Bcl-XL expression. 47, 48 Those cytokines induce differentiation, erythropoiesis, and thrombopoiesis, which might benefit low-risk MDS but might also put high-risk patients, such as MLL-PTD ϩ patients, at risk for clonal expansion of abnormal HSPCs.
In conclusion, the Mll PTD/WT mouse model provides unique genetic and biochemical tools to identify new targets and pathways responsible for the altered differentiation/repopulating properties, self-renewal activity, lineage bias, and myeloid differentiation blockade relevant to MLL-PTD MDS and AML. This model should also help us to understand the underlying mechanism(s) for each of the phenotypes we found in this study and facilitate improved therapies and patient outcomes in the future.
